The Study Group: Dr M. Henzgen, Jena; Dr W. Feußner, Kassel; Dr R. Dominicus, Dülmen; Dr Chr. Männer, Arnsberg; Dr D. Stiller, Fürstenwalde; Dr S. Hofmann, Potsdam; Dr H. Scholz, Mahlow; Dr D. Futschik, Dresden; Dr C.J. Corrigan, London; Dr K. Rajakulasingam, London.
Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid
Article first published online: 21 APR 2005
Volume 60, Issue 6, pages 801–807, June 2005
How to Cite
Corrigan, C. J., the Study Group, Kettner, J., Doemer, C., Cromwell, O. and Narkus, A. (2005), Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy, 60: 801–807. doi: 10.1111/j.1398-9995.2005.00790.x
- Issue published online: 21 APR 2005
- Article first published online: 21 APR 2005
- Accepted for publication 3 November 2004
- grass pollen;
- hay fever;
- short-term immunotherapy;
- specific immunotherapy
Background: The clinical efficacy and safety of a six-grass pollen allergoid has been studied. The advent of more exacting clinical guidelines and a better appreciation of the possible mechanisms of treatment prompted this reappraisal.
Methods: A 2-year double-blind multicentre placebo-controlled phase 3 clinical trial was undertaken in 154 patients suffering symptoms of rhinoconjunctivitis with or without asthma (GINA I or II). Therapy comprised two consecutive preseasonal short-courses of subcutaneous injections using a grass pollen allergoid adsorbed to aluminium hydroxide.
Results: A combined symptom and medication score (SMS) was used as the primary end-point for clinical efficacy. SMS from the first year showed a significant difference of 26.6% between the two study groups (P = 0.026) and this was improved after the second year when there was a 48.4% difference in SMS between active and placebo treatment in favour of the allergoid (P = 0.018). Highly significant increases in grass pollen allergen-specific IgG1 and IgG4 antibody concentrations were measured in association with active treatment. Allergen tolerance was increased as judged by a conjunctival provocation test and significant improvements in quality of life were documented using a standardized questionnaire. The allergoid was well tolerated.
Conclusions: The grass pollen allergoid was shown to be safe and clinically efficacious in the management of hay fever with or without asthma (GINA I or II).